Astellas Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPMY research report →
About the company
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas.
- CEO
- Naoki Okamura
- IPO
- 2009
- Employees
- 14,754
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $23.83B
- P/E
- 13.22
- P/S
- 1.80
- P/B
- 2.11
- EV/EBITDA
- 6.98
- Div Yield
- 3.62%
- Gross Margin
- 76.08%
- Op Margin
- 18.92%
- Net Margin
- 13.63%
- ROE
- 17.44%
- ROIC
- 12.08%
- Revenue
- $2.27T · 18.61%
- Net Income
- $309.12B · 509.13%
- EPS
- $172.56 · 508.68%
- Op Income
- $445.01B
- FCF YoY
- 293.05%
- 52W High
- $17.35
- 52W Low
- $9.22
- 50D MA
- $13.97
- 200D MA
- $13.67
- Beta
- 0.08
- Avg Volume
- 183.82K
Get TickerSpark's AI analysis on ALPMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALPMY coverage
Recent articles, reports, and earnings notes.
No research on ALPMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALPMY report →Similar companies
Peers in the same neighborhood.